pI: 3.9288 |
Length (AA): 3157 |
MW (Da): 309540 |
Paralog Number:
18
Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 14 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 173 | 5xfs (B) | 1 | 172 | 52.00 | 0 | 1 | 0.508399 | 1.55 |
2 | 174 | 4w4k (B) | 2 | 173 | 32.00 | 0 | 0.67 | 0.219699 | 1.57 |
60 | 103 | 4x8w (H) | 1 | 303 | 57.00 | 0.68 | 0.09 | 0.154537 | 4.27 |
272 | 464 | 1olr (A) | 22 | 216 | 16.00 | 0 | 0.16 | 0.051834 | 0.06 |
283 | 460 | 3p4g (A) | 37 | 236 | 32.00 | 0.12 | 0.78 | 0.345983 | -0.63 |
320 | 427 | 3ult (A) | 11 | 116 | 25.00 | 0 | 0.02 | 0.25991 | -0.91 |
682 | 835 | 5in2 (A) | 10 | 156 | 33.00 | 0.19 | 0.08 | 0.17338 | 0.52 |
1262 | 1655 | 3bry (A) | 4 | 432 | 14.00 | 0 | 0.09 | 0.090502 | 0.87 |
1367 | 1499 | 5dns (B) | 56 | 197 | 34.00 | 0.32 | 0.58 | 0.381729 | -0.83 |
1367 | 1499 | 4yc5 (A) | 56 | 189 | 32.00 | 0.62 | 0.34 | 0.465729 | -1.11 |
1477 | 1638 | 3akq (A) | 2 | 173 | 25.00 | 0 | 0.9 | 0.253015 | -0.31 |
1489 | 1641 | 3exu (B) | 2 | 183 | 18.00 | 0 | 0.39 | 0.107164 | -0.19 |
1876 | 2115 | 2bwr (A) | 133 | 372 | 31.00 | 0.97 | 0.18 | 0.0456215 | 0.87 |
2662 | 2819 | 1oqv (A) | 30 | 194 | 16.00 | 0 | 0.08 | 0.171748 | -0.57 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Dormant phase. | murphy |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Dormant phase. | hasan |
hasan | Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. |
murphy | Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. |
Ortholog group members (OG5_132376)
Species | Accession | Gene Product |
---|---|---|
Babesia bovis | BBOV_II003500 | hypothetical protein |
Mycobacterium tuberculosis | Rv0442c | PPE family protein PPE10 |
Mycobacterium tuberculosis | Rv2356c | PPE family protein PPE40 |
Mycobacterium tuberculosis | Rv3144c | PPE family protein PPE52 |
Mycobacterium tuberculosis | Rv0755c | PPE family protein PPE12 |
Mycobacterium tuberculosis | Rv0878c | PPE family protein PPE13 |
Mycobacterium tuberculosis | Rv1135c | PPE family protein PPE16 |
Mycobacterium tuberculosis | Rv1548c | PPE family protein PPE21 |
Mycobacterium tuberculosis | Rv1753c | PPE family protein PPE24 |
Mycobacterium tuberculosis | Rv1917c | PPE family protein PPE34 |
Mycobacterium tuberculosis | Rv1918c | PPE family protein PPE35 |
Mycobacterium tuberculosis | Rv2353c | PPE family protein PPE39 |
Mycobacterium tuberculosis | Rv0304c | PPE family protein PPE5 |
Mycobacterium tuberculosis | Rv3159c | PPE family protein PPE53 |
Mycobacterium tuberculosis | Rv3343c | PPE family protein PPE54 |
Mycobacterium tuberculosis | Rv3347c | PPE family protein PPE55 |
Mycobacterium tuberculosis | Rv3350c | PPE family protein PPE56 |
Mycobacterium tuberculosis | Rv0305c | PPE family protein PPE6 |
Mycobacterium tuberculosis | Rv3558 | PPE family protein PPE64 |
Mycobacterium tuberculosis | Rv0355c | PPE family protein PPE8 |
Mycobacterium ulcerans | MUL_0098 | PPE family protein |
Mycobacterium ulcerans | MUL_1395 | PPE family protein |
Mycobacterium ulcerans | MUL_0890 | PPE family protein |
Mycobacterium ulcerans | MUL_0782 | PPE family protein |
Mycobacterium ulcerans | MUL_0902 | PPE family protein |
Mycobacterium ulcerans | MUL_0965 | PPE family protein |
Mycobacterium ulcerans | MUL_0964 | PPE family protein |
Mycobacterium ulcerans | MUL_4491 | PPE family protein |
Plasmodium falciparum | PF3D7_0201900 | erythrocyte membrane protein 3 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu769 | Mycobacterium tuberculosis | essential | nmpdr |
mtu894 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu1155 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu1783 | Mycobacterium tuberculosis | essential | nmpdr |
mtu1948 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu1949 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu307 | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu3403 | Mycobacterium tuberculosis | essential | nmpdr |
mtu308 | Mycobacterium tuberculosis | non-essential | nmpdr |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3